Washington Doctor Sues DEA Over Psilocybin

Doctor Sues DEA Over Magic Mushrooms and End-of-Life Therapy

A Seattle doctor hoping to expand access to psilocybin (aka “magic mushrooms”) for terminally ill cancer patients is suing the US Drug Enforcement Administration, or DEA. The doctor is taking the DEA to court after recent denial of an application to legally use the psilocybin in end-of-life treatment.

for terminally ill cancer patients is suing the DEA to overturn the agency’s recent denial of an application to legally use the psychedelic in end-of-life treatment

Attorneys filed a lawsuit this month in the US Circuit Court of Appeals for the Ninth Circuit, arguing the DEA’s denial of the application was unfounded. They’re now asking judges to throw the decision out and force the agency to “expeditiously reconsider and accommodate valid requests made from qualified health providers for the therapeutic use of the eligible investigation drug psilocybin.”

“It is a first-of-its-kind lawsuit,” lead attorney Kathyn Tucker said on a press call. “The case is about seeking to ensure that patients with serious, life-threatening illness are able to realize the promise of state and federal right-to-try laws and access psilocybin.”

The push to expand patient access began last year. Dr. Sunil Aggarwal, who specializes in end-of-life care, began searching for a legal way to obtain psilocybin for treating patients. In November, he began applying to state and federal regulators for approval to cultivate psilocybin mushrooms and use them in treatment.

“We know that it’s a naturally occurring substance that we can cultivate safely, we know how to dose it, and there’s really good reason to believe it can help,” Aggarwal said at the time.

Aggarwal’s team argues psilocybin should be made available under state and federal right-to-try laws — relatively new policies that give patients with terminal conditions the opportunity to try investigational medications that have not been approved for general use. Washington state adopted a right-to-try law in 2017 before then President Donald Trump signed the federal Right to Try Act the next year. Dozens of other states also have right-to-try laws on their books these days.

Aggarwal and the clinic where he works, the Advanced Integrative Medical Science (AIMS) Institute, wrote to the DEA seeking guidance on how to move forward on psilocybin under right-to-try laws, because it remains a Schedule I controlled substance even as numerous localities, including Washington, DC and the entire state of Oregon have now basically decriminalized the plant. 

“What we hoped the DEA would be doing under right-to-try is creating a user-friendly approach to how clinicians like Dr. Aggarwal can navigate the system to obtain an eligible investigational drug for an eligible patient,” Tucker said on the press call.

The DEA rejected the application, replying in a Feb. 12 letter that the agency lacks the authority to waive the federal Controlled Substances Act, despite what the federal Right to Try Act says. The only way to dispense psilocybin legally, the DEA added, would be to apply for a federal research permit, which “would not be applicable to Dr. Aggarwal at this time.”

In response, Aggarwal and the AIMS Institute filed their petition for review. Aggarwal criticized the DEA’s decision as an obstacle for terminally ill patients who simply want to improve their quality of life.

“This is absolutely unacceptable for their care, because they have this right under the law, and the law states that that medicines like this should be made available expeditiously for patients,” Aggarwal said. “I’m hoping that the judges who look at that will take into consideration the great potential [of psilocybin], the suffering of my patients, and the law and what their rights are.”

Tucker, the lead attorney in the suit, explained psilocybin seems to fit the criteria listed in state and federal right-to-try laws, having completed a Phase I research trial and remaining under active investigation. 

“Psilocybin, hence, is what the right-to-try laws designate as an eligible investigational drug”

Kathyn Tucker said.

The team noted that health regulators in Canada have already extended legal exemptions to certain patients seeking to use psilocybin in end-of-life care. Officials there granted the first such exemption in August of last year, and in December the country’s health minister said some therapists and health care professionals could also legally use the drug.

One of the patients represented in the new lawsuit is Erinn Baldeschweiler, a mother of two who has been diagnosed with stage four metastatic breast cancer. Psilocybin, she believes, could help ease the emotional trauma of a terminal diagnosis. “Whatever remaining time I have left,” Baldeschwiler said, “I want to have the highest quality of life.”

This isn’t the first time the DEA has found itself battling lawsuits over the criminalization of controlled substances that hold therapeutic value.

Scientists and veterans sued the federal agency last year, arguing the legal basis the DEA has used to justify keeping marijuana in Schedule I of the Controlled Substances Act is unconstitutional. They asked for a review of its decisions to reject rescheduling petitions in 2020, 2016 and 1992. The DEA subsequently requested the court dismiss the suit.

The agency has also been taken to court over delays in approving additional cannabis manufacturers for research purposes.

The Scottsdale Research Institute alleged the DEA has been deliberately using delay tactics to avoid approving cultivation applications. A court mandated the agency take steps to make good on its promise. The suit was dropped after the DEA provided a status update.

In March 2020, the DEA finally unveiled a revised rule change proposal, which it said was necessary due to the high volume of applicants and to address potential complications related to international treaties to which the US is a party.

But the new psychedelics-related litigation is unique and reflects the growing public interest in loosening laws governing plant- and fungi-based materials, particularly for medical use.

This piece is a part of a content sharing arrangement between The News Station and Marijuana Moment.

Kyle Jaeger is Marijuana Moment's Los Angeles-based associate editor. His work has also appeared in High Times, VICE, etc.

Kyle Jaeger is Marijuana Moment's Los Angeles-based associate editor. His work has also appeared in High Times, VICE, etc.

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!